Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

SOLARCAINE SEVERE SUNBURN RELIEF SPRAY "SERIOUSLY MISBRANDED" and subject to possible enforcement action, FDA told Schering-Plough in a Nov. 5 reg letter. The agency said it considers the lidocaine/aloe vera product "seriously misbranded" in that it "is not aware of any substantial scientific evidence which establishes that a formulation of lidocaine, aloe vera and other ingredients...are generally recognized as safe and effective [GRAS/E] for the treatment of severe sunburn and severe sunburn pain and healing sun damaged skin." The 2% lidocaine product is new this year. The 1983 OTC External Analgesic Drug Products TFM lists 0.5% to 4% lidocaine as GRAS/E for "the temporary relief of pain...associated with minor burns [and] sunburn," FDA noted. In addition, FDA said it is not aware of any OTC drug containing the Solarcaine formula - lidocaine alone or in combination with aloe vera - marketed in the U.S. prior to the Dec. 4, 1975 cut-off date for exemption from OTC review with indications for "severe sunburn," "severe sunburn pain" or to "heal sun damaged skin." FDA also warned that it is "seriously concerned" with the way the product is marketed since severe sunburn and sunburn pain are "potential health hazards" that require physician attention. The product has been promoted in print ads as a treatment for a "preschool child with a severe sunburn over most of the child's body," according to FDA. "This promotion and other statements and representations in the labeling present a potential health hazard," the agency maintains, since the conditions the ad claims that the product treats "are not amenable to self diagnosis and treatment by the laity." The reg letter also charges that Solarcaine Pure Aloe Severe Sunburn Relief Spray is in "serious violation" of the FD&C Act section 502(a) for labeling that is mis-branded and "false and misleading." The product's warning label is misleading and "contradictory" in that it says to consult a physician but offers the product for self treatment. Further, the label is misleading in that it includes "pure aloe" in the name and "features the term `aloe' in juxtaposition with and in larger type than the only declared active ingredient, lidocaine, and otherwise features aloe vera in a manner that creates an impression of greater value...while at the same time failing to declare 'aloe vera gel' as an active ingredient," FDA said. The agency also charges that the product is a drug, lidocaine topical aerosol, which is listed in the United States Pharmacopeia, and should therefore be required to state the concentration of lidocaine present. In addition, the product does not carry adequate directions for use and is an unapproved new drug for the conditions it claims to treat. The letter, from Office of Compliance Director Daniel Michels to Plough Personal Care Group President Michael Pietrangelo, gave the company 10 days to respond. Plough met with the agency on Nov. 22, FDA said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts